Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Gains from Investment Securities (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Gains from Investment Securities data on record, last reported at $728995.0 in Q3 2021.

  • For Q3 2021, Gains from Investment Securities changed N/A year-over-year to $728995.0; the TTM value through Sep 2021 reached $728995.0, changed N/A, while the annual FY2024 figure was $100000.0, 1350.0% up from the prior year.
  • Gains from Investment Securities reached $728995.0 in Q3 2021 per COGT's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.5 million in Q2 2020 and bottomed at -$5.2 million in Q4 2020.
  • Average Gains from Investment Securities over 4 years is $1.1 million, with a median of $868961.5 recorded in 2018.
  • The widest YoY moves for Gains from Investment Securities: up 449266.3% in 2020, down 334.79% in 2020.
  • A 4-year view of Gains from Investment Securities shows it stood at $873528.0 in 2018, then surged by 152.08% to $2.2 million in 2019, then plummeted by 334.79% to -$5.2 million in 2020, then skyrocketed by 114.1% to $728995.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $728995.0 in Q3 2021, $4.1 million in Q2 2021, and $864395.0 in Q1 2021.